Faculty Opinions recommendation of IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis.

Author(s):  
Patricia Elizalde
Cancer Cell ◽  
2020 ◽  
Vol 38 (3) ◽  
pp. 412-423.e9 ◽  
Author(s):  
Rasmus Siersbæk ◽  
Valentina Scabia ◽  
Sankari Nagarajan ◽  
Igor Chernukhin ◽  
Evangelia K. Papachristou ◽  
...  

2019 ◽  
Vol 20 (6) ◽  
pp. 1419 ◽  
Author(s):  
Rachel A. Sabol ◽  
Adam Beighley ◽  
Paulina Giacomelli ◽  
Rachel M. Wise ◽  
Mark A. A. Harrison ◽  
...  

Adipose stem cells (ASCs) play an essential role in tumor microenvironments. These cells are altered by obesity (obASCs) and previous studies have shown that obASCs secrete higher levels of leptin. Increased leptin, which upregulates estrogen receptor alpha (ERα) and aromatase, enhances estrogen bioavailability and signaling in estrogen receptor positive (ER+) breast cancer (BC) tumor growth and metastasis. In this study, we evaluate the effect of obASCs on ER+BC outside of the ERα signaling axis using breast cancer models with constitutively active ERα resulting from clinically relevant mutations (Y537S and D538G). We found that while obASCs promote tumor growth and proliferation, it occurs mostly through abrogated estrogen signaling when BC has constitutive ER activity. However, obASCs have a similar promotion of metastasis irrespective of ER status, demonstrating that obASC promotion of metastasis may not be completely estrogen dependent. We found that obASCs upregulate two genes in both ER wild type (WT) and ER mutant (MUT) BC: SERPINE1 and ABCB1. This study demonstrates that obASCs promote metastasis in ER WT and MUT xenografts and an ER MUT patient derived xenograft (PDX) model. However, obASCs promote tumor growth only in ER WT xenografts.


2018 ◽  
Author(s):  
Sabrina Tripolt ◽  
Vanessa M. Knab ◽  
Heidi A. Neubauer ◽  
Dominik P. Elmer ◽  
Fritz Aberger ◽  
...  

AbstractThe opioid crisis of pain medication bears risks from addiction to cancer progression, but little experimental facts exist. Expression of δ-opioid receptors (DORs) correlates with poor prognosis for breast cancer (BCa) patients, but mechanism and genetic/pharmacologic proof of key changes in opioid-triggered cancer biology are lacking. We show that oncogenic STAT3 signaling and E-Cadherin downregulation are triggered by opioid-ligated DORs, promoting metastasis. Human and murine transplanted BCa cells (MDA-MB-231, 4T1) displayed enhanced metastasis upon opioid-induced DOR stimulation, and DOR-antagonist blocked metastasis. Opioid-exposed BCa cells showed enhanced migration, STAT3 activation, down-regulation of E-Cadherin and expression of epithelial-mesenchymal transition (EMT) markers. STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced BCa cell metastasis and migration. We conclude that opioids trigger metastasis through oncogenic JAK1/2-STAT3 signaling.


Sign in / Sign up

Export Citation Format

Share Document